Blocked By Sublocade: Braeburn Sues To Get Brixadi Buprenorphine Formulation Onto Market

Lawsuit against US FDA challenges scope of three-year exclusivity awarded to Indivior’s Sublocade, the first monthly depot formulation of buprenorphine for treating opioid use disorder.